


Buenos Aires Breast Cancer Symposium

BA-BCS2024

September 3 – 6, 2024
IFIBYNE AUDITORIUM
FCEN-UBA



Program

SEPTEMBER 3

15:00-17:45 Registration

17:45-18:00 Welcome from organizers

18:00-19:00 **Opening Conference**

Chairs: Claudia Lanari, IBYME-CONICET, Buenos Aires, Argentina and Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.

Robert Clarke, University of Manchester, Manchester, UK

The role of cytokines in regulating cancer stem cells in therapy-resistance and metastasis

19:00-20:00 Welcome Reception at IFIBYNE

SEPTEMBER 4

9:30-11:00 **Session 1: Luminal breast cancer**

Chairs: Caroline Lamb, IBYME-CONICET, Buenos Aires, Argentina.
María F. Rubio, IDIM-UBA-CONICET, Buenos Aires, Argentina.
Fernando Petracci, Instituto Alexander Fleming, Buenos Aires, Argentina.

09:30-10:00 **Todd Miller**

Medical College of Wisconsin Cancer Center, Milwaukee, USA.
Leveraging endocrine and metabolic vulnerabilities in ER+ breast cancer.

10:00-10:30 **Joseph Jerry**

University of Massachusetts, Amherst, USA.
Metabolism, Signaling and Breast Cancer Riskcells from donors differing in breast cancer risk: variation in barriers to immortalization and estrogen signaling.

10:30-10:45 **Abstract selected for oral presentation:**

RUNX2 expression correlates with tumor progression in luminal breast cancer patients. **Yamil D Mahmoud**, IBYME-CONICET.

10:45-11:00 Discussion

11:00-11:30 **Coffee Break**

11:30-13:00 **Session 2: New treatments for Luminal and Her2+ breast cancer**

Chairs: Natalia Rubinstein, iB3, FCEyN, UBA, Buenos Aires, Argentina and Vanina Medina, BIOMED-CONICET, UCA, Buenos Aires, Argentina

11:30-12:00 **Jennifer Richer**

University of Colorado, Aurora, USA.

AR action in ER+ breast cancer – preclinical and clinical trial updates

12:00-12:30 **Federico Waisberg**

Instituto Fleming, Buenos Aires

New treatments and biomarkers in hormone resistant (HR+) breast cancer.

12:30-12:45 **Abstract selected for oral presentation:**

Inhibition of Rac1 activity enhances Tostuzumab sensitivity in Her2-positive breast cancer cells through cell cycle deregulation, **Virginia Judith Wolos**, Instituto de Oncología Ángel Roffo.

12.45-13:00 Discussion

13:00-15:00 **Lunch and Poster Session 1**

14:40-15:00 Sponsor presentation: LOBOV Científica

15:00-17:00 **Session 3: Detection and treatment of TNBC**

Chairs: Roxana Schillaci, IBYME-CONICET, Buenos Aires, Argentina and Maria José Rico, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.

15:00-15:30 **Roger Chammas**

Center for Translational Research in Oncology, University of São Paulo, Brazil.

miRNAs as biomarkers for early onset Triple Negative Breast Cancers.

15:30-16:00 **Paolo Ceppi**

University of Southern Denmark, Odense, Denmark.

Propionate suppresses epithelial-to-mesenchymal transition and reduces the aggressiveness of lung carcinoma, can we extrapolate to breast cancer?

16:00-16:30 **Pablo Mandó**

CEMIC, Buenos Aires, Argentina.

New therapeutic options for TNBC.

16:30-16:45 **Abstract selected for oral presentation:**

Enhancing Paclitaxel efficacy in triple negative breast cancer through DKC1 inhibition with R1D2-10, **Roman Nicolas Vilarullo**, Universidad Nacional de Quilmes.

16:45-17:00 Discussion

17:00-17:30 Coffee break

17:30-19.00 Round Table 1 (Spanish)

Coordinadoras: Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina y María Roqué, IHEM-CONICET, Mendoza, Argentina.

Utilidad clínica de la búsqueda de marcadores circulantes en biopsia líquida, para el redireccionamiento y/o seguimiento de la carga tumoral en pacientes con cáncer de mama.

Adriana De Siervi IBYME-CONICET y Oncoliq, Buenos Aires, Argentina.

Javier Stigliano, Hospital Nacional Prof. A Posadas, Haedo, Argentina.

Manglio Rizzo, Departamento Oncología, Hospital Universitario Austral, Pilar, Argentina.

Julieta Pandolfi, Anatomía Patológica. Lab. Secuenciación. Hospital Italiano de Buenos Aires, Argentina.

Diego Marzese (participante virtual) Division of Surgical Oncology, Duke University School of Medicine (DUSM), Durham, USA.

SEPTEMBER 5

09:30-11:15 Session 4: Cancer Stem Cells and Tumor Initiation

Chairs: Albana Gattelli, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Catalina Lodillinsky, Instituto Ángel Roffo, Buenos Aires, Argentina

09:30-10:00 Fariba Behbod

University of Kansas, Kansas City, USA.

Ductal carcinoma in situ: Transcriptional diversity and stemness.

10:00-10:30 Jochen Maurer

University Hospital RWTH, Aachen, Germany.

Cancer stem cells as disease models in research – opportunities and challenges.

10:30-11:00 William Muller

Rosalind and Morris Goodman Cancer Center, Montreal, Canada.

Oncogene-mediated regulation of tumor immune microenvironment in mouse models of human breast cancer

11:00-11:15 Discussion

11:15-11:45 **Coffee Break**

11:45-13:30 **Session 5: Breast Cancer Genomics and Transcriptomics**

Chairs: Ignacio Schor, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Marianela Candolfi, INBIOMED, FMED, UBA, Buenos Aires, Argentina.

11:45-12:15 **Martin Abba**

Universidad Nacional de La Plata, Buenos Aires, Argentina
Old questions, new tools

12:15-12:45 **Pedram Razavi**

Memorial Sloan Kettering Cancer Center, New York City, USA.
Deciphering the genomic mechanisms of resistance to CDK4/6 inhibitors

12:45-13:00 **Gonzalo Gomez Abuin**

Hospital Alemán, Buenos Aires
Utility of next generation sequencing in breast cancer

13:00-13:15 **Abstract selected for oral presentation:**

Exploring the effects of non-coding somatic mutations in BAF complex deregulation and the malignant characteristics of triple-negative breast cancer, **Pedro J. Salaberry**, IFIBYNE-UBA-CONICET.

13:15-13:30 Discussion

13:30-15:00 Lunch and Poster Session 2

15:00-17:00 Session 6: immunotherapy and Fighting treatment resistance

Chairs: Georgina Coló, INIBIBB-UNS, Bahía Blanca, Argentina and Germán A. Gil, CIQUIBIC, UNC-CONICET), Córdoba, Argentina

15:00-15:30 **Adrian Lee**

University of Pittsburgh, Pittsburgh, USA.
Endocrine resistance in breast cancer metastasis.

15:30-16:00 **Dejan Juric**

Massachusetts General Hospital, Boston, USA.
Novel PI3Ki inhibitors including mutant-selective PI3K inhibitors

16:00-16:30 **María Vivanco**

CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.
Breast Cancer Heterogeneity and resistance to hormone therapy

16:30-16:45 **Abstract selected for oral presentation:**

Preclinical and clinical role of MUC4/TNF axis in metastatic triple-negative breast cancer, **Florencia Mauro**, IBYME-CONICET.

16:45-17:00 Discussion

17:00-17:30 Coffee Break

17:30-19:00 Round Table 2 (Spanish)

Coordinadores: Mario Rossi Universidad Austral, Pilar, Argentina y Pablo Mandó, CEMIC, Buenos Aires, Argentina

Jerarquización en investigación dentro de la carrera de formación de los médicos, experiencias en CEMIC, Fleming y Austral.

Manglio Rizzo, Servicio de Oncología Hospital Austral, Pilar, Argentina.

Fernando Petracci, Instituto Fleming, Buenos Aires, Argentina.

Estrella Levy, Instituto Fleming, Buenos Aires, Argentina.

SEPTEMBER 6

09:30-11:15 **Session 7: Early detection and treatment**

Chairs: Giselle Peters, Instituto Ángel Roffo, Buenos Aires, Argentina and Leandro E. Mainetti, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.

09:30-10:00 **Vanesa Gottifredi**

Instituto Leloir, Buenos Aires, Argentina.

Targeting the chromosomic instability induced by cancer therapy.

10:00-10:30 **Catherine Park**

University of California, San Francisco, USA.

Evolution of breast radiotherapy options for today's early stage patients.

10:30-10:45 **Adriana de Siervi**

Oncoliq, CABA-Argentina.

miRNAs for early cancer detection in liquid biopsy.

10:45-11:00 **Abstract selected for oral presentation**

SPARC: a potential biomarker of the transition from in situ to Invasive breast cancer, **Marianela Sciacca**, Instituto de Oncología Ángel Roffo, Buenos Aires, Argentina.

11:00-11:15 Discussion

11:15-11:45 Coffee Break

11:45-13:30 **Session 8: Understanding and modeling breast cancer subtypes**

Chairs: Paola Rojas, IBYME-CONICET, Buenos Aires, Argentina and María T. Branham, IHEM-CONICET, Mendoza, Argentina

11:45-12:15 **Steffi Oesterreich**

University of Pittsburgh, Pittsburgh, USA.

Invasive lobular breast cancer – what's different and why is this important?

12:15-12:45 **Alana Welm**

University of Utah, Salt Lake City, Utah, USA.

Using patient-derived models for drug discovery and functional precision oncology in advanced breast cancer

12:45-13:00 **Abstract selected for oral presentation:**

RET receptor integrates tumor cell-adipocyte communication to promote breast cancer. **Sabrina A. Vallone**, IFIBYNE-UBA-CONICET.

13:00-13:15 **Abstract selected for oral presentation:**

Progesterone promotes triple-negative breast cancer metastasis through RANKL-expressing Treg cells. **Tomas Dalotto**, IBYME-CONICET.

13:15-13:30 Discussion

13:30-15:00 Lunch and Poster Session 3

15:00-16:00 **Session 9: Improving life quality**

Chair: Mario Rossi, Universidad Austral, Pilar, Argentina and Virginia Novaro, IBYME-CONICET, Buenos Aires

15:15-15:45 **Syril Pettit**,

Health and Environmental Sciences Institute (HESI), Washington DC, USA.
Addressing Cancer Therapy Related Adverse Effects – An Opportunity to Improve Quality of Life and Outcome for Patients.

15:45-16:00 Discussion

16:00-17:00 **Closing Conference**

Chairs: Martin Abba, Universidad Nacional de La Plata, Buenos Aires, Argentina and Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina.

Katherine Hoadley

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.

Quantitative Medicine for Breast Cancer Patients.

17:00-17:15 Discussion and closing remarks by the organizers

17:15-17:30 Coffee break

17:30-19:00 **Round Table 3 (Spanish)**

Coordinadores: Virginia Novaro, IBYME-CONICET, Buenos Aires, Argentina y Federico Waisberg, Instituto A. Fleming, Buenos Aires, Argentina.

Navegación en el sistema de salud para pacientes con bajo y alto riesgo de cáncer de mama. Situación actual en la región Norte, Centro y Sur del país.

Alejandro Di Sibio coordinador del Programa Nacional de Control de Cáncer de Mama del Instituto Nacional del Cáncer, Buenos Aires, Argentina

Marcela Kober del Instituto Misionero del Cáncer, Posadas, Argentina.

Romina Yapur, Hospital Villa Regina de Río Negro y Centro Oncológico Integral, General Roca, Argentina.